4dmedical Ltd. · ASX:4DX
4dmedical — Investor Presentation (October 2024)
20 slides from 4dmedical's investor presentation, Oct 1, 2024
Slide 1: See beyond the structure
See beyond the structure 4DMedical Limited (ASX:4DX) Investor Presentation 1 October 2024
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by 4DMedical Limited (ACN 161 684 831) (Company or 4DMedical). This presentation contains summary information about the Company, its subsidiaries and the entities, businesses and assets they own and operate (Group) and their activities current as of 1 O
Slide 3: Global respiratory diagnostic market valued at US$31.4 billion per annum
Global respiratory diagnostic market valued at US$31.4 billion per annum Four existing lung diagnostic technologies account for 99% of all lung scans: Country Spend Procedures ($USD) Expenditure (USD $B) U.S.A 13,716M 73.5M 20 Others 4,964M 59.8M Germany 2,678M 20.3M Japan 1,905M 22.8M 15 Procedures
Slide 4: Current lung diagnostics are failing us
Current lung diagnostics are failing us Lung health screening Unexplained dyspnoea Burn Pits & DRRD (COPD, silicosis, black lung, lung cancer) (shortness of breath) (Deployment-related Respiratory Disease) ▪ COPD – 4th largest cause of ▪ $12.2bn cost of breathlessness in Australia2 ▪ >6million servi
Slide 5: Comprehensive chest diagnostics product suite
Comprehensive chest diagnostics product suite CT LVAS Aortic Aneurysm2 CT:VQ2 RV/LV XV Scanner2 VA Initiatives Coronary LDAf Artery Calcification XV Technology Partnerships Lung Texture LDAi Analysis1 Case Studies Clinical Insights Lung Nodules IQ-UIP2 XV LVAS 1. CE Mark 5 2. FDA Clearance pending;
Slide 6: A complete lung health solution
A complete lung health solution Pulmonary Structure Pulmonary Function Cardiovascular Total Solution Lung Density* XV LVAS®* CAC* Combined product Coronary Calcification/Heart Emphysema, HAA, Fissures Dynamic Ventilation suite Analysis (Fluoro) Disease Enabling access to key imaging modalities: CT,
Slide 7: Solving the clinical conundrum for doctors across multiple care areas
Solving the clinical conundrum for doctors across multiple care areas Clinical Conundrum in Clinical Tools Needed to Applications for Technologies in Clinical Lung Assessment Solve the Conundrum Practice A mismatch between clinical Functional lung analysis providing Unexplained dyspnoea Example tech
Slide 8: FY24 achievements – building the foundations
FY24 achievements – building the foundations Philips Expansion in AU ➢ Master Reseller Agreement executed US reimbursement & ➢ Commercial agreement ➢ Significant expansion of commercialisation signed with Jones commercial coverage Radiology in Adelaide across multiple sectors ➢ US Medicare in the la
Slide 9: Commercial Update
Commercial Update call. me ats cA
Slide 10: Commercialisation strategy
Commercialisation strategy US Government US Commercial Global Partnerships Australia Enablers Philips Olympus I-MED Exclusive Non-exclusive Genentech Jones Radiology Reimbursement Nuance/Aidoc/Blackford Integral Diagnostics Sector Veterans Affairs Community-based Clinics Global Pharma Companies Comm
Slide 11: VA opportunity
VA opportunity Veterans Affairs opportunity Progress to date Next steps • VA opportunity significant and • 4DMedical well positioned to urgent, with PACT Act expected provide screening services – • Onboarding multiple spend of $280 Billion over 10 successful burn pits trial at outpatient Clinics to
Slide 12: US reimbursement – XV LVAS® and CT LVAS
US reimbursement – XV LVAS® and CT LVAS 1 We addressed three key 2 We engaged with key 3 CMS reimbursement was components of industry bodies for approved reimbursement support and approval ✓ American Medical Association ✓ Clinical data Code – describing the procedure CPT Panel and Advisors demonstra
Slide 13: Philips Update
Philips Update 13
Slide 14: Philips overview
Philips overview Philips Healthcare – portfolio of businesses2 €18.2bn in sales (2023), ~70% in #1 or #2 positions; ~40% sales recurring revenue; ~70k employees 42% North America, 21% Western Europe, 9% other mature geographies, 28% growth geographies Personal health: Diagnosis & treatment: Connecte
Slide 15: Philips reseller agreement
Philips reseller agreement The Reseller Agreement The opportunity • Philips has long established and significant existing 1 partnership with both the VA and DoD, spanning 45 years • Philips & 4DMedical to work together to Background support the need for scalable, non-invasive • 50% of VA clinics usi
Slide 16: FY25 outlook
FY25 outlook 16
Slide 17: Product update: major disruptive breakthroughs on the horizon
Product update Major disruptive breakthroughs on the horizon in large market segments CT:VQ IQ-UIP “CT:VQ” represents a significant IQ-UIP is an AI algorithm that disruptive breakthrough in identifies patients with radiological respiratory imaging workflow usual interstitial pneumonia (UIP) transiti
Slide 18: FY25 outlook
FY25 outlook Research and Product US Government Development • Veterans Affairs • Department of Defense • CT:VQ FDA submission and approval • Federal and State Facilities • IQ-IUP FDA Submission progressing and stakeholders with Breakthrough • XV ScannerTM deployments generate clinical evidence and w
Slide 19: Executive team
Executive team Dr ANDREAS FOURAS PhD MATT TUCKER SIMON GLOVER Dr GREG MOGEL MD Managing Director and CEO Chief Commercial Officer Chief Financial Officer Chief Medical Officer Award-winning aerospace engineer and innovator Seasoned executive leader, board member and Experienced ASX-listed MedTech co
Slide 20: 4DMedical Limited (ASX:4DX) Investor Presentation
4DMedical Limited (ASX:4DX) Investor Presentation 1 October 2024 Copyright ©4DMedical Limited 2024 Level 7, Melbourne Connect 700 Swanston Street Melbourne, Victoria 3053 Australia www.4dmedical.com ABN 31 161 684 831